Genelux Co. (NASDAQ:GNLX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Genelux in a research note issued on Tuesday, April 2nd. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.26) for the quarter. HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for Genelux's current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux's Q2 2024 earnings at ($0.26) EPS, Q3 2024 earnings at ($0.25) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.03) EPS, FY2025 earnings at ($1.39) EPS, FY2026 earnings at ($0.96) EPS and FY2027 earnings at ($0.42) EPS.
Separately, Benchmark reaffirmed a "speculative buy" rating and issued a $30.00 price target on shares of Genelux in a research report on Wednesday.
View Our Latest Stock Report on Genelux
Genelux Trading Down 2.7 %
Shares of NASDAQ:GNLX traded down $0.13 during midday trading on Thursday, hitting $4.73. The company's stock had a trading volume of 206,991 shares, compared to its average volume of 120,103. The stock's 50 day simple moving average is $7.38 and its 200 day simple moving average is $13.14. Genelux has a fifty-two week low of $4.51 and a fifty-two week high of $40.98.
Institutional Investors Weigh In On Genelux
A number of institutional investors have recently added to or reduced their stakes in the company. AE Wealth Management LLC boosted its holdings in Genelux by 1,370.0% during the third quarter. AE Wealth Management LLC now owns 194,875 shares of the company's stock valued at $4,772,000 after purchasing an additional 181,618 shares in the last quarter. D.A. Davidson & CO. acquired a new stake in Genelux during the third quarter valued at approximately $237,000. Advisor Resource Council acquired a new stake in Genelux during the fourth quarter valued at approximately $233,000. Barclays PLC boosted its holdings in Genelux by 516.4% during the third quarter. Barclays PLC now owns 3,384 shares of the company's stock valued at $83,000 after purchasing an additional 2,835 shares in the last quarter. Finally, Whittier Trust Co. acquired a new stake in Genelux during the third quarter valued at approximately $175,000. 37.33% of the stock is owned by institutional investors and hedge funds.
Genelux Company Profile
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Featured Articles
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
